Urinary Excretion of MicroRNA-126 Is a Biomarker for Hemangioma Proliferation

    loading  Checking for direct PDF access through Ovid

Excerpt

We have read the article entitled “Urinary Excretion of MicroRNA-126 Is a Biomarker for Hemangioma Proliferation” by Biswas et al.1 with great interest. The evaluation of the short noncoding RNA molecule microRNA-126 in the urine of children, as an element that could potentially assess hemangioma reaction to therapies, seems to be a smart, easy, and useful tool that can be used as a prognostic factor and hemangioma proliferation biomarker.
However, microRNA-126 has been both a tumor suppressor and an oncogene, depending on the type of cancer.2 It is also suspected to play a role in pathologic entities such as diabetes,3 cystic fibrosis,4 and allergic asthma,5 among many pathologic conditions. This fact underlines the lack of specificity of microRNA-126 as a hemangioma-only reliable marker.
Given the fact that microRNA-126 human microRNA is expressed mainly in the endothelial cells of blood vessels, it can potentially control angiogenesis and function in hemangiomas of early childhood. Other biomarkers that could probably be used in combination, such as 8-oxo-2′-deoxyguanosine, could be also investigated in human urine to increase specificity of hemangioma markers.
In conclusion, further research is needed with the aim of determining reliable biomarkers as prognostic tools in hemangioma treatment. In addition, specificity is a factor that needs to be considered.

Related Topics

    loading  Loading Related Articles